Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $22.25

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been assigned a consensus rating of “Hold” from the seven analysts that are covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $22.25.

Several research analysts have recently issued reports on ACRS shares. Cantor Fitzgerald restated a “neutral” rating on shares of Aclaris Therapeutics in a report on Friday, January 12th. StockNews.com downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, April 2nd. HC Wainwright downgraded shares of Aclaris Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, January 22nd. Finally, BTIG Research reiterated a “neutral” rating on shares of Aclaris Therapeutics in a research report on Thursday, January 11th.

Aclaris Therapeutics Stock Up 3.8 %

NASDAQ ACRS opened at $1.36 on Friday. Aclaris Therapeutics has a 52 week low of $0.59 and a 52 week high of $11.12. The stock has a market capitalization of $96.91 million, a PE ratio of -1.07 and a beta of 0.23. The firm has a 50 day moving average of $1.23 and a two-hundred day moving average of $1.59.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.07. Aclaris Therapeutics had a negative net margin of 283.15% and a negative return on equity of 64.56%. The business had revenue of $17.57 million during the quarter, compared to analysts’ expectations of $3.96 million. On average, equities research analysts expect that Aclaris Therapeutics will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets raised its position in Aclaris Therapeutics by 10.9% during the 1st quarter. BNP Paribas Financial Markets now owns 241,101 shares of the biotechnology company’s stock worth $299,000 after buying an additional 23,747 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in Aclaris Therapeutics during the 1st quarter worth $39,000. BML Capital Management LLC raised its position in Aclaris Therapeutics by 1,338.7% during the 1st quarter. BML Capital Management LLC now owns 9,395,934 shares of the biotechnology company’s stock worth $11,651,000 after buying an additional 8,742,827 shares during the last quarter. Octagon Capital Advisors LP purchased a new position in shares of Aclaris Therapeutics in the 4th quarter valued at about $105,000. Finally, Bain Capital Life Sciences Investors LLC increased its holdings in shares of Aclaris Therapeutics by 2.9% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 3,500,000 shares of the biotechnology company’s stock valued at $3,675,000 after purchasing an additional 100,000 shares in the last quarter. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.